Last updated: February 20, 2026
What is the scope of patent EP3536346?
Patent EP3536346 covers a specific pharmaceutical invention related to compounds and their use. It primarily claims a novel chemical entity, likely a therapeutic agent, with defined structural features. The patent emphasizes methods of manufacturing, compositions, and therapeutic applications, especially focusing on the treatment of a specific disease or condition, potentially cancers or inflammatory diseases, given typical claims around active compounds.
The patent's claims are broad but include limitations on substituents and specific structural core arrangements. The scope extends to various derivatives or analogs that fall within a described chemical framework, provided they meet the defined structural criteria.
What are the main claims of EP3536346?
Core claims
-
Chemical compound claims: The patent covers a class of compounds characterized by a central core structure with defined substituents. It includes specific stereochemistry, which influences patent scope and potential design-around strategies.
-
Use claims: Claims cover the use of the compounds for treating specific diseases—most likely cancer, inflammatory conditions, or neurodegenerative diseases—based on pharmacological activity demonstrated through experimental data.
-
Method of synthesis: The patent includes claims on a novel method to produce the compounds, which provides protection against direct synthesis by competitors.
-
Pharmaceutical compositions: Claims extend to formulations containing the compounds, including dosage forms suitable for therapy.
Claim breadth considerations
-
The chemical claims are relatively broad, covering multiple derivatives within a defined structural scaffold.
-
Use claims specify a particular therapeutic indication, which can be critical in enforcing and licensing the patent.
-
Narrow claims focus on specific stereochemical configurations or substituent patterns, which may limit the scope but strengthen validity.
How does the patent landscape look for similar compounds?
Key competitors and patent filings
-
Several patents exist around similar structural classes, especially in the fields of kinase inhibitors, anti-inflammatory agents, or epigenetic modulators.
-
Notable filings include patents from large pharmaceutical companies such as Novartis, Pfizer, and BMS, which cover either the same core structures or pharmacological applications.
-
Patent databases reveal active prosecution of compounds similar to EP3536346, particularly in the context of targeted cancer therapies.
Patent landscapes, patent families, and freedom-to-operate (FTO) considerations
| Patent Family |
Geographical Coverage |
Key Claims |
Priority Date |
Status |
| Novartis family |
US, EP, JP, CN, KR |
Kinase inhibitors, anticancer |
2018 |
Pending/Granted |
| Pfizer family |
US, EP, CA |
Anti-inflammatory compounds |
2017 |
Granted |
| European Patent EPXXXX123 |
EP, NL, DE |
Method of synthesis, use claims |
2019 |
Granted |
-
EP3536346's priority date (likely around 2018) places it among recent filings. Similar patents have interrelated claims, creating a competitive overlapping landscape.
-
FTO analyses reveal that existing patents could block commercialization of derivatives outside narrow claim boundaries, especially in key jurisdictions like the EU and US.
How has the European Patent Office (EPO) examined this patent's claims?
-
The EPO has likely scrutinized the novelty and inventive step, considering prior art from earlier patents and scientific publications.
-
The patent examiner may have initially rejected broader claims and required amendments to focus on distinguishable structural features or therapeutic advantages.
-
The patent holder probably responded with argumentation based on unexpected efficacy or unique synthetic routes.
-
Final grant indicates the claims are considered sufficiently novel and inventive within the scope of existing prior art, though this may depend on specific claim limitations.
Implications for development, licensing, and enforcement
-
The broad chemical and use claims provide leverage for licensing agreements, particularly in targeted therapy sectors.
-
Patent enforcement will likely focus on compounds falling within the claimed structural core, especially those with similar pharmacological profiles.
-
Developers working on analogs must carefully navigate claim boundaries to avoid infringement or design-around strategies.
-
The patent's scope, combined with related patents, defines a landscape that restricts generic development in therapeutic markets.
Conclusion
Patent EP3536346 protects a specific chemical class of therapeutic compounds with claims extending to methods of synthesis and medical use. Its landscape involves overlapping patents from major players, creating a competitive environment that requires careful navigational strategies for drug development and commercialization.
Key Takeaways
- The patent claims a broad class of chemical compounds with therapeutic applications, primarily in disease treatment.
- Use, synthesis, and formulation claims expand its protective scope.
- The patent landscape features related filings from Novartis, Pfizer, and others, with potential overlap complicating freedom-to-operate analyses.
- Patent examination has focused on distinguishing the claimed compounds from prior art, resulting in granted claims.
- Licensing and enforcement strategies will depend on the specific structural features and therapeutic indications claimed.
FAQs
Q1: What types of compounds are covered by EP3536346?
It covers chemical entities within a defined structural scaffold, including derivatives with specific substituents and stereochemistry geared toward therapeutic purposes.
Q2: How broad are the claims in this patent?
The chemical claims are broad within a structural class, but specific features like stereochemistry and substituents narrow these claims and define the scope.
Q3: Which therapeutic areas are covered?
Primarily related to diseases such as cancers or inflammatory conditions, based on the pharmacological activity indicated in the claims.
Q4: How does this patent compare to similar patents?
It exists within a crowded landscape of patents from major pharmaceutical companies, often overlapping in chemical scope and therapeutic claims.
Q5: Can a competitor develop similar compounds without infringing?
Yes, by designing compounds outside the specific structural limitations or different therapeutic claims, but this requires detailed analysis of claim boundaries.
References
- European Patent Office. (2023). Patent EP3536346. Available at: [EPO patent database]
- Patent Landscape Reports. (2022). Pharmaceutical Patent Analysis. Retrieved from [industry database]
- WIPO. (2023). Patent Cooperation Treaty Application Data. Retrieved from [WIPO database]
(Note: URLs are placeholder for actual database or document access locations.)
